Top

Published in:

01-03-2013 | Epidemiology (J Gelfand, Section Editor)

Update on the Epidemiology of Melanoma

Authors: Steven T. Chen, Alan C. Geller, Hensin Tsao

Published in: Current Dermatology Reports | Issue 1/2013

Abstract

Cutaneous malignant melanoma (CMM) has been increasing steadily in incidence during the past 30 years. Recent studies have explored associations between CMM and varying physiologic risk factors, such as nevi or hair and eye color, in addition to historical features, such as a personal history of nonmelanoma skin cancer (NMSC), childhood cancers, Parkinson’s disease, hormone exposure, and family history of CMM. Genome-wide association studies also have uncovered many genetic determinants of CMM risk. Ultimately, ultraviolet (UV) radiation exposure remains the most important modifiable risk factor for CMM. Organ transplant recipients and nonsteroidal anti-inflammatory usage also may play a role. Whereas risk factors are important to identify, effective campaigns to reduce the burden of disease through early detection and prevention are essential. We present detailed data regarding these facets of care for the CMM patient and provide an update on the epidemiology of CMM.

Cancer Facts and Figures. In: Society AC (ed) Edition Atlanta, GA: 2012.

Shoo BA, Kashani-Sabet M. Melanoma arising in African-, Asian-, Latino- and Native-American populations. Semin Cutan Med Surg. 2009;28:96–102.PubMedCrossRef

Linos E, Swetter SM, Cockburn MG, et al. Increasing burden of melanoma in the United States. J Invest Dermatol. 2009;129:1666–74.PubMedCrossRef

Purdue MP, Freeman LE, Anderson WF, Tucker MA. Recent trends in incidence of cutaneous melanoma among US Caucasian young adults. J Invest Dermatol. 2008;128:2905–8.PubMedCrossRef

Reed KB, Brewer JD, Lohse CM, et al. Increasing incidence of melanoma among young adults: an epidemiological study in Olmsted County, Minnesota. Mayo Clin Proc. 2012;87:328–34.PubMedCrossRef

Tucker MA. Melanoma epidemiology. Hematol Oncol Clin N Am. 2009;23:383–95. vii.CrossRef

Wolchok J. How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma. Ann Oncol. 2012;23 Suppl 8:viii15–21.PubMedCrossRef

Seidler AM, Pennie ML, Veledar E, et al. Economic burden of melanoma in the elderly population: population-based analysis of the surveillance, epidemiology, and End results (SEER)–Medicare data. Arch Dermatol. 2010;146:249–56.PubMedCrossRef

Tsao H, Rogers GS, Sober AJ. An estimate of the annual direct cost of treating cutaneous melanoma. J Am Acad Dermatol. 1998;38:669–80.PubMedCrossRef

10.

Chu EY, Wanat KA, Miller CJ et al. Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study. J Am Acad Dermatol 2012.

11.

Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer. 2005;41:28–44.PubMedCrossRef

12.

Olsen CM, Carroll HJ, Whiteman DC. Estimating the attributable fraction for cancer: a meta-analysis of nevi and melanoma. Cancer Prev Res (Phila). 2010;3:233–45.CrossRef

13.

Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer. 2005;41:2040–59.PubMedCrossRef

14.

Wheless L, Black J, Alberg AJ. Nonmelanoma skin cancer and the risk of second primary cancers: a systematic review. Cancer Epidemiol Biomarkers Prev. 2010;19:1686–95.PubMedCrossRef

15.

Pappo AS, Armstrong GT, Liu W et al. Melanoma as a subsequent neoplasm in adult survivors of childhood cancer: A report from the childhood cancer survivor study. Pediatr Blood Cancer 2012.

16.

Bajaj A, Driver JA, Schernhammer ES. Parkinson's disease and cancer risk: a systematic review and meta-analysis. Cancer Causes Control. 2010;21:697–707.PubMedCrossRef

17.

Liu R, Gao X, Lu Y, Chen H. Meta-analysis of the relationship between Parkinson disease and melanoma. Neurology. 2011;76:2002–9.PubMedCrossRef

18.

Gao X, Simon KC, Han J, et al. Genetic determinants of hair color and Parkinson's disease risk. Ann Neurol. 2009;65:76–82.PubMedCrossRef

19.

Gandini S, Iodice S, Koomen E, et al. Hormonal and reproductive factors in relation to melanoma in women: current review and meta-analysis. Eur J Cancer. 2011;47:2607–17.PubMedCrossRef

20.

Karagas MR, Stukel TA, Dykes J, et al. A pooled analysis of 10 case–control studies of melanoma and oral contraceptive use. Br J Cancer. 2002;86:1085–92.PubMedCrossRef

21.

Randerson-Moor JA, Taylor JC, Elliott F, et al. Vitamin D receptor gene polymorphisms, serum 25-hydroxyvitamin D levels, and melanoma: UK case–control comparisons and a meta-analysis of published VDR data. Eur J Cancer. 2009;45:3271–81.PubMedCrossRef

22.

Asgari MM, Maruti SS, Kushi LH, White E. A cohort study of vitamin D intake and melanoma risk. J Invest Dermatol. 2009;129:1675–80.PubMedCrossRef

23.

• Udayakumar D, Tsao H. Melanoma genetics: an update on risk-associated genes. Hematol Oncol Clin N Am 2009; 23: 415–429, vii. Authors review genes of variable risk implicated in CMM, most notably CDKN2A.

24.

Njauw CN, Kim I, Piris A, et al. Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. PLoS One. 2012;7:e35295.PubMedCrossRef

25.

Raimondi S, Sera F, Gandini S, et al. MC1R variants, melanoma and red hair color phenotype: a meta-analysis. Int J Cancer. 2008;122:2753–60.PubMedCrossRef

26.

Palmer JS, Duffy DL, Box NF, et al. Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? Am J Hum Genet. 2000;66:176–86.PubMedCrossRef

27.

Matichard E, Verpillat P, Meziani R, et al. Melanocortin 1 receptor (MC1R) gene variants may increase the risk of melanoma in France independently of clinical risk factors and UV exposure. J Med Genet. 2004;41:e13.PubMedCrossRef

28.

Stratigos AJ, Dimisianos G, Nikolaou V, et al. Melanocortin receptor-1 gene polymorphisms and the risk of cutaneous melanoma in a low-risk southern European population. J Invest Dermatol. 2006;126:1842–9.PubMedCrossRef

29.

Williams PF, Olsen CM, Hayward NK, Whiteman DC. Melanocortin 1 receptor and risk of cutaneous melanoma: a meta-analysis and estimates of population burden. Int J Cancer. 2011;129:1730–40.PubMedCrossRef

30.

•• Chatzinasiou F, Lill CM, Kypreou K, et al. Comprehensive field synopsis and systematic meta-analyses of genetic association studies in cutaneous melanoma. J Natl Cancer Inst. 2011;103:1227–35. A review and meta-analysis of genetic factors associated with CMM. This review also contains data from GWAS papers to review SNP associations with CMM.PubMedCrossRef

31.

Hayward NK. Genetics of melanoma predisposition. Oncogene. 2003;22:3053–62.PubMedCrossRef

32.

Box NF, Duffy DL, Chen W, et al. MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am J Hum Genet. 2001;69:765–73.PubMedCrossRef

33.

Fargnoli MC, Gandini S, Peris K, et al. MC1R variants increase melanoma risk in families with CDKN2A mutations: a meta-analysis. Eur J Cancer. 2010;46:1413–20.PubMedCrossRef

34.

Brown KM, Macgregor S, Montgomery GW, et al. Common sequence variants on 20q11.22 confer melanoma susceptibility. Nat Genet. 2008;40:838–40.PubMedCrossRef

35.

Bishop DT, Demenais F, Iles MM, et al. Genome-wide association study identifies three loci associated with melanoma risk. Nat Genet. 2009;41:920–5.PubMedCrossRef

36.

Duffy DL, Zhao ZZ, Sturm RA, et al. Multiple pigmentation gene polymorphisms account for a substantial proportion of risk of cutaneous malignant melanoma. J Invest Dermatol. 2010;130:520–8.PubMedCrossRef

37.

Falchi M, Bataille V, Hayward NK, et al. Genome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi. Nat Genet. 2009;41:915–9.PubMedCrossRef

38.

Duffy DL, Iles MM, Glass D, et al. IRF4 variants have age-specific effects on nevus count and predispose to melanoma. Am J Hum Genet. 2010;87:6–16.PubMedCrossRef

39.

Amos CI, Wang LE, Lee JE, et al. Genome-wide association study identifies novel loci predisposing to cutaneous melanoma. Hum Mol Genet. 2011;20:5012–23.PubMedCrossRef

40.

Barrett JH, Iles MM, Harland M, et al. Genome-wide association study identifies three new melanoma susceptibility loci. Nat Genet. 2011;43:1108–13.PubMedCrossRef

41.

Macgregor S, Montgomery GW, Liu JZ, et al. Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3. Nat Genet. 2011;43:1114–8.PubMedCrossRef

42.

Law MH, Montgomery GW, Brown KM, et al. Meta-analysis combining new and existing data sets confirms that the TERT-CLPTM1L locus influences melanoma risk. J Invest Dermatol. 2012;132:485–7.PubMedCrossRef

43.

Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer. 2005;41:45–60.PubMedCrossRef

44.

Berwick M, Chen YT. Reliability of reported sunburn history in a case–control study of cutaneous malignant melanoma. Am J Epidemiol. 1995;141:1033–7.PubMed

45.

Weinstock MA, Colditz GA, Willett WC, et al. Recall (report) bias and reliability in the retrospective assessment of melanoma risk. Am J Epidemiol. 1991;133:240–5.PubMed

46.

Cockburn M, Hamilton A, Mack T. Recall bias in self-reported melanoma risk factors. Am J Epidemiol. 2001;153:1021–6.PubMedCrossRef

47.

Ouhtit A, Nakazawa H, Armstrong BK, et al. UV-radiation-specific p53 mutation frequency in normal skin as a predictor of risk of basal cell carcinoma. J Natl Cancer Inst. 1998;90:523–31.PubMedCrossRef

48.

Rigel DS, Rigel EG, Rigel AC. Effects of altitude and latitude on ambient UVB radiation. J Am Acad Dermatol. 1999;40:114–6.PubMedCrossRef

49.

Bulliard JL. Site-specific risk of cutaneous malignant melanoma and pattern of sun exposure in New Zealand. Int J Cancer. 2000;85:627–32.PubMedCrossRef

50.

Parisi AV, Kimlin MG, Lester R, Turnbull D. Lower body anatomical distribution of solar ultraviolet radiation on the human form in standing and sitting postures. J Photochem Photobiol B. 2003;69:1–6.PubMedCrossRef

51.

Holman CD, Armstrong BK. Cutaneous malignant melanoma and indicators of total accumulated exposure to the sun: an analysis separating histogenetic types. J Natl Cancer Inst. 1984;73:75–82.PubMed

52.

Pfahlberg A, Kolmel KF, Gefeller O. Timing of excessive ultraviolet radiation and melanoma: epidemiology does not support the existence of a critical period of high susceptibility to solar ultraviolet radiation- induced melanoma. Br J Dermatol. 2001;144:471–5.PubMedCrossRef

53.

Han J, Colditz GA, Hunter DJ. Risk factors for skin cancers: a nested case–control study within the Nurses' Health Study. Int J Epidemiol. 2006;35:1514–21.PubMedCrossRef

54.

Lazovich D, Vogel RI, Berwick M, et al. Indoor tanning and risk of melanoma: a case–control study in a highly exposed population. Cancer Epidemiol Biomarkers Prev. 2010;19:1557–68.PubMedCrossRef

55.

•• Gandini S, Autier P, Boniol M. Reviews on sun exposure and artificial light and melanoma. Prog Biophys Mol Biol. 2011;107:362–6. A recent review article covering risk of UV exposure and CMM diagnosis. Particular attention is paid to tanning booth usage and subsequent risk of CMM.PubMedCrossRef

56.

Cust AE, Armstrong BK, Goumas C, et al. Sunbed use during adolescence and early adulthood is associated with increased risk of early-onset melanoma. Int J Cancer. 2011;128:2425–35.PubMedCrossRef

57.

• Boniol M, Autier P, Boyle P, Gandini S. Cutaneous melanoma attributable to sunbed use: systematic review and meta-analysis. BMJ. 2012;345:e4757. Authors perform a meta-analysis to specifically explore the risk imparted for CMM from tanning booth usage.PubMedCrossRef

58.

Brewer JD, Christenson LJ, Weaver AL, et al. Malignant melanoma in solid transplant recipients: collection of database cases and comparison with surveillance, epidemiology, and end results data for outcome analysis. Arch Dermatol. 2011;147:790–6.PubMedCrossRef

59.

Engels EA, Pfeiffer RM, Fraumeni Jr JF, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011;306:1891–901.PubMedCrossRef

60.

Johannesdottir SA, Chang ET, Mehnert F, et al. Nonsteroidal anti-inflammatory drugs and the risk of skin cancer: a population-based case–control study. Cancer. 2012;118:4768–76.PubMedCrossRef

61.

Long MD, Martin CF, Pipkin CA et al. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 143: 390–399 e391.

62.

Breitbart EW, Waldmann A, Nolte S, et al. Systematic skin cancer screening in Northern Germany. J Am Acad Dermatol. 2012;66:201–11.PubMedCrossRef

63.

• Katalinic A, Waldmann A, Weinstock MA, et al. Does skin cancer screening save lives? An observational study comparing trends in melanoma mortality in regions with and without screening. Cancer. 2012;118:5395–402. Data presented by authors support the idea that systematic screening can decrease CMM mortality.PubMedCrossRef

64.

Pasco S, Brassart B, Ramont L, et al. Control of melanoma cell invasion by type IV collagen. Cancer Detect Prev. 2005;29:260–6.PubMedCrossRef

65.

• Green AC, Williams GM, Logan V, Strutton GM. Reduced melanoma after regular sunscreen use: randomized trial follow-up. J Clin Oncol. 2011;29:257–63. Authors demonstrate decreased incidence of CMM with sunscreen usage for prevention.PubMedCrossRef

Title: Update on the Epidemiology of Melanoma
Authors: Steven T. Chen
Alan C. Geller
Hensin Tsao
Publication date: 01-03-2013
Publisher: Current Science Inc.
Published in: Current Dermatology Reports / Issue 1/2013
Electronic ISSN: 2162-4933
DOI: https://doi.org/10.1007/s13671-012-0035-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Update on the Epidemiology of Melanoma

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2013

The Role of IL-21 in Chronic Inflammatory Skin Diseases

Update on Epidemiology of Cutaneous T-Cell Lymphoma

Chronic Spontaneous Urticaria: the Emerging Role of Coagulation

Epidemiology and Natural History of Psoriatic Arthritis: an UpdateWhat Dermatologists Need to Know

Update on Epidemiology and Clinical Assessment Tools of Cutaneous Lupus Erythematosus and Dermatomyositis

Risk Factors for Psoriasis